Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 741-751

  Park, Byeong Woo ^a   Park, Seho ^a   Park, Hyung Seok ^a   Koo, Ja Seung ^a   Yang, Woo Ick ^a   Lee, Jun Sang ^a   Hwang, Hyewon ^a   Kim, Seung Il ^a   Lee, Kyong Sik ^b  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Breast neoplasms; Cyclooxygenase 2; Ki 67; Prognosis; Progression; Proliferation

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84863717156     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1971-2     Document Type: Article

References (33)

1. Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365. doi: 10.1200/JCO.2003.04.576
2. Zerkowski MP, Camp RL, Burtness BA et al (2007) Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Investig 25:19-26. doi:10.1080/07357900601128825
3. Amir M, Agarwal HK (2005) Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 60:563-570
4. Sheng H, Shao J, Morrow JD et al (1998) Modulation of apop-tosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362-366
5. Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31:2-11
6. Singh B, Berry JA, Shoher A et al (2005) COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26:1393-1399
7. Rolland PH, Martin PM, Jacquemier J et al (1980) Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64:1061-1070
8. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174-183. doi:10.1016/S1470-2045(09)70262-1
9. Boland GP, Butt IS, Prasad R et al (2004) COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90:423-429. doi:10.1038/sj.bjc.6601534
10. Wulfing P, Diallo R, Muller C et al (2003) Analysis of cyclo-oxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129:375-382. doi:10.1007/s00432-003-0459-1
11. Ristimaki A, Sivula A, Lundin J et al (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632-635
12. Subbaramaiah K, Norton L, Gerald W et al (2002) Cyclooxy-genase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-18657. doi:10.1074/jbc.M111415200
13. Kelly LM, Hill AD, Kennedy S et al (2003) Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29:707-710
14. O'Connor JK, Avent J, Lee RJ et al (2004) Cyclooxygenase-2 expression correlates with diminished survival in invasive breast cancer treated with mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys 58:1034-1040. doi:10.1016/j.ijrobp.2003.08.032
15. Ranger GS, Jewell A, Thomas V et al (2004) Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers. J Surg Oncol 88:100-103. doi:10.1002/jso.20142
16. Spizzo G, Gastl G, Wolf D et al (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88:574-578. doi:10.1038/sj.bjc. 6600741
17. Half E, Tang XM, Gwyn K et al (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676-1681
18. Denkert C, Winzer KJ, Muller BM et al (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97:2978-2987. doi:10.1002/cncr.11437
19. Jalava P, Kuopio T, Juntti-Patinen L et al (2006) Ki67 immu-nohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histo-pathology 48:674-682. doi:10.1111/j.1365-2559.2006.02402.x
20. Kerlikowske K, Molinaro AM, Gauthier ML et al (2010) Bio-marker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102:627-637. doi:10.1093/jnci/djq101
21. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184. doi:10.1093/jnci/dji237
22. Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York
23. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histo-pathology 19:403-410
24. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795. doi:10.1200/JCO.2009.25.6529
25. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145. doi: 10.1200/JCO.2006.09.2775
26. Soslow RA, Dannenberg AJ, Rush D et al (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645
27. Lim SC (2003) Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Oncol Rep 10:1241-1249
28. Glover JA, Hughes CM, Cantwell MM et al (2011) A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microin-vasive carcinoma of the breast and invasive breast cancer. Br J Cancer 105:13-17. doi:10.1038/bjc.2011.204
29. Rozenowicz RL, Santos RE, Silva MA et al (2010) Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. Rev Col Bras Cir 37:323-327. doi:S0100-69912010000500003
30. Witton CJ, Hawe SJ, Cooke TG et al (2004) Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45:47-54. doi:10.1111/j.1365-2559.2004.01898.x
31. Howe LR (2007) Inflammation and breast cancer. Cycloox-ygenase/ prostaglandin signaling and breast cancer. Breast Cancer Res 9:210. doi:10.1186/bcr1678
32. Singh-Ranger G, Salhab M, Mokbel K (2008) The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109:189-198. doi:10.1007/s10549-007-9641-5
33. Food and Drug Administration (FDA) (2010) FDA begins process to remove breast cancer indication from Avastin label. http://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm237172.htm. Accessed 16 Dec 2010